Accessibility Menu
 
Taysha Gene Therapies logo

Taysha Gene Therapies

(NASDAQ) TSHA

Current Price$6.43
Market Cap$1.85B
Since IPO (2020)-73%
5 Year-73%
1 Year+419%
1 Month+44%

Taysha Gene Therapies Financials at a Glance

Market Cap

$1.85B

Revenue (TTM)

$9.77M

Net Income (TTM)

$108.99M

EPS (TTM)

$-0.36

P/E Ratio

-17.84

Dividend

$0.00

Beta (Volatility)

1.76 (High)

Price

$6.43

Volume

177,450

Open

$6.09

Previous Close

$6.43

Daily Range

$5.93 - $6.50

52-Week Range

$1.22 - $6.50

TSHA News

No articles available.

TSHA: Motley Fool Moneyball Superscore

59

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Taysha Gene Therapies

Industry

Biotechnology

Employees

99

CEO

Sean P. Nolan

Headquarters

Dallas, TX 75247, US

TSHA Financials

Key Financial Metrics (TTM)

Gross Margin

94%

Operating Margin

-11%

Net Income Margin

-11%

Return on Equity

-68%

Return on Capital

-35%

Return on Assets

-32%

Earnings Yield

-5.61%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.85B

Shares Outstanding

287.27M

Volume

177.45K

Short Interest

0.00%

Avg. Volume

2.81M

Financials (TTM)

Gross Profit

$8.63M

Operating Income

$110.50M

EBITDA

$109.35M

Operating Cash Flow

$93.09M

Capital Expenditure

$738.00K

Free Cash Flow

$93.83M

Cash & ST Invst.

$319.77M

Total Debt

$18.17M

Taysha Gene Therapies Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$5.49M

+171.3%

Gross Profit

$5.19M

+156.5%

Gross Margin

94.55%

N/A

Market Cap

$1.85B

N/A

Market Cap/Employee

$25.30M

N/A

Employees

73

N/A

Net Income

$27.85M

-48.3%

EBITDA

$28.00M

-51.7%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$301.60M

+297.6%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$18.17M

-70.4%

Short Term Debt

$0.00

-100.0%

Return on Assets

-31.75%

N/A

Return on Invested Capital

-34.88%

N/A

Free Cash Flow

$26.97M

-47.3%

Operating Cash Flow

$26.72M

-46.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ANABAnaptysBio, Inc.
$67.51+0.91%
NKTRNektar Therapeutics
$84.86+1.04%
OCSOculis Holding AG
$27.46+0.33%
IMTXImmatics N.V.
$11.17+2.76%

Trending Stocks

Symbol / CompanyPricePrice Chg
EFOIEnergy Focus
$6.49+2.11%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$13.90+0.06%
INTCIntel
$68.50+0.00%
TQQQProShares Trust - ProShares UltraPro Qqq
$58.59+0.04%

Questions About TSHA

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.